TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03532165

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Lower extremity Ultrasound
Description: One group may forego a CT angiogram of the chest if they have a positive lower extremity ultrasound. The other group with a negative ultrasound may still require CT angiogram imaging.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Lower extremity Ultrasound
Description: One group may forego a CT angiogram of the chest if they have a positive lower extremity ultrasound. The other group with a negative ultrasound may still require CT angiogram imaging.
Study: NCT01774552

Intervention type: DEVICE
Intervention: Photo Acoustic Microscopy and Optical Coherence tomography
Description: Photo Acoustic Microscopy and Optical Coherence tomography
Study: NCT01838668

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo capsules orally BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: Two dimethyl fumarate 120mg capsules orally BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: Two dimethyl fumarate 120mg capsules orally BID
Study: NCT02984085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genetically corrected cultured epidermal autograft (ATMP)
Description: Genetically corrected cultured epidermal autograft (Hologene 7) is intended for transplantation onto surgically prepared blistering skin areas of RDEB patients and permanent regeneration of a healthy, functional and renewing epidermis sustained by the engraftment of transduced epidermal stem cells.~By taking some autologous epidermal cells, a new layer of transgenic tissue is grown in the laboratory. This layer of tissue is then implanted by a surgeon into the damaged area. The implantation can be done in one or more areas and repeated in case of failure of the first surgery.
Study: NCT03963024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning treatment Treosulfan-TMI
Description: Treosulfan i.v.: 14 g/m²/d (day -6 to -4) Fludarabine i.v.: 30 mg/m²/d (day -6 to -2) Antithymocyte globulin (ATG)-Fresenius i.v.: 5/0 mg/kg (day -4 to -2) Mabthera i.v.: 200/0\* mg/m2 (day -1) TMI: (10 Gy) 2 Gy bis in die (BID) (day -2 to -1) or TMI: (12 Gy) 2 Gy BID (day -3 to -1) or TMI: (14 Gy) 2 Gy BID (day -3 to -1)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SCT
Description: Stem Cell Transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GvHD prophylaxis
Description: Rapamycin p.o.: 4 mg/d, (target 8-15 ng/ml) (starting day -7) Mycofenolate mofetile: 10 mg/kg tid, (Maximum dose 720 mg/tid) (starting from day 0)
Study: NCT03153761

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD170201AA
Description: A moist snuff product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD170201AA
Description: A moist snuff product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD170201AB
Description: A moist snuff product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD170201AB
Description: A moist snuff product
Study: NCT02894879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreatheMAX®
Description: Modify chest physical therapy~* oscillated incentive spirometry (OIS) with inspiratory load of 5-8 cm H2O 30 times/set~* oscillated positive expiratory pressure (OPEP) with expiratory load of 5-8 cm H2O 30 times/set~* Coughing with splinting 3 times/set~* Chest mobilization with overhead both arms rises 10 times/set total 5 set/day
Study: NCT04500418

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cenicriviroc (CVC)
Description: Treatment with Cenicriviroc tablets of 150mg. (450g/300g on day 1 and 300mg/d on days 2-28).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Optically identical pills without CVC.
Study: NCT02049450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib
Description: Ruxolitinib was taken at a starting dose of 10 mg twice daily with dose adjustments within the range of 5 to 25 mg twice daily.
Study: NCT02115932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength & Balance Training
Description: Subjects will be guided through 8 weeks (1 hour per week) of home-based strength and balance training sessions. During each session, a trainer will guide subjects to perform muscle strengthening, range of motion, static balance, dynamic balance and endurance exercises, after an initial warm up. They will also be given advice on continuing such training as well as daily walking for the rest of the week.
Study: NCT03619681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN026
Description: Patient will be intravenously administrated with one dose of KN026. dosing interval may be adjusted during the study based on emerging data from this trial and/or from other trial.
Study: NCT00609518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m\^2 intravenous infusion on day 1 of each 21-day cycle. Number of Cycles: Until progression or to a maximum of 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: 500 mg/m\^2 intravenous infusion on day 1 of each 21-day cycle. Number of Cycles: Until progression or to a maximum of 6 cycles.
Study: NCT02894879

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Routine treatment
Description: Routine chest physical therapy~* Deep breathing exercise (upper and lower costal and diaphragmatic breathing exercise) as deep as possible for 10 times/set/level~* Coughing with splinting 3 times/set~* Chest mobilization with overhead both arms raised 10 times/set total 5 set/day
Study: NCT00609518

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid
Description: 350-1000 micrograms taken orally for at least 5 daily doses during the 7-day period prior to the first dose of pemetrexed then continues daily throughout treatment until 3 weeks after the last dose of pemetrexed.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: 350-1000 micrograms taken orally for two consecutive daily doses of folic acid the day before and the day of the first dose of pemetrexed the continues throughout treatment and for 3 weeks after the last dose of pemetrexed.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: 1000 micrograms intramuscular injection of vitamin B12 during the week prior to the first dose of pemetrexed then further injections given approximately every 9 weeks until 3 weeks after the last dose of pemetrexed.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12
Description: 1000 micrograms intramuscular injection of vitamin B12 during the week prior to the first dose of pemetrexed then further injections given approximately every 9 weeks until 3 weeks after the last dose of pemetrexed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: 4 mg taken orally \[or equivalent\] twice per day the day before, the day of, and the day after the first day of pemetrexed. Continue to give dexamethasone twice per day the day before, the day of, and the day after each dose of pemetrexed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 4 mg taken orally \[or equivalent\] twice per day on the day of the first dose of pemetrexed. Continue to give dexamethasone twice per day on the day of each dose of pemetrexed.
Study: NCT03483727

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIMMAXMARCHERYAN
Description: Digital cognitive aid during the management of simulated combat wounded.
Study: NCT03628885

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Top Concern Tailored Intervention
Description: General Vaccine Information video plus a brief (\< 50 sec) animated video address the parent's top ranked question or concern from the provided list of possible concerns.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: All Concerns Tailored Intervention
Description: General Vaccine Information video plus one or more brief (\< 50 sec) animated videos that address all of the parent's indicated question or concern from the provided list of possible concerns.
Study: NCT01216618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InsuPatch
Description: the InsuPatchTM device includes a heating pad and electronics. The heating pad is attached to an existing insulin infusion set by a simple procedure.
Study: NCT00928707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea
Description: 50 mg o.d. of GIVINOSTAT + MTD of HU monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea
Description: 50 mg b.i.d. of GIVINOSTAT + MTD HU monotherapy
Study: NCT03322735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25-30mg/m2/day IV for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: cyclophosphamide 0.6-0.8g/m2/day IV for 2 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA CAR-T
Description: BCMA CAR-T cells will be administered after completion of the chemotherapy.
Study: NCT01741051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEPA Filter
Study: NCT03122925

Intervention type: DEVICE
Intervention: MR
Description: MR

Intervention type: DEVICE
Intervention: MR
Description: MR
Study: NCT01235195

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline hydrochloride
Description: 50 mg capsule, single-dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline hydrochloride
Description: 50 mg tablet, single-dose
Study: NCT02834676

Intervention type: DRUG
Intervention: Gelified Ethanol
Description: Pain relief with chemonucleolysis by using gelified ethanol regard to age, sex, ASA score, and complications.
Study: NCT02817945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NOTA-3P-TATE-RGD
Description: 68Ga-NOTA-3P-TATE-RGD were injected into the patients before the PET/CT scans
Study: NCT05055752

Intervention type: DRUG
Group type: OTHER
Intervention: Pharmaceutical-lipid aspirin (PL-ASA)
Description: Subjects receive the first drug, followed by a 7-day washout period, then receive the second drug.

Intervention type: DRUG
Group type: OTHER
Intervention: Pharmaceutical-lipid aspirin (PL-ASA)
Description: Subjects receive the first drug, followed by a 7-day washout period, then receive the second drug.
Study: NCT02438137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dimethyl fumarate
Description: Dimethyl fumarate capsules will be dispensed during routine study appointments. 120 mg tablets will be dispensed to facilitate dose titrations. Drug will be dispensed in 1 month supply, so that compliance can be reconciled at monthly follow-up visits, and recorded in accountability logs. Participants will be instructed to take the medication with food, in the morning and at dinnertime. If participants miss a dose, they will be instructed to resume their normal dose at the next scheduled time, and be instructed not to take an extra dose at their next dosing interval if they previously miss a dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will be dispensed during routine study appointments. Placebo will be dispensed in 1 month supply, so that compliance can be reconciled at monthly follow-up visits, and recorded in accountability logs. Participants will be instructed to take the placebo with food, in the morning and at dinnertime. If participants miss a dose, they will be instructed to resume their normal dose at the next scheduled time, and be instructed not to take an extra dose at their next dosing interval if they previously miss a dose.
Study: NCT02364739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written information
Description: Brochure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written and oral information
Description: Written information consists in a brochure with information about fertility, while oral information consists in a tailored oral explanation about the wrong answers to the pre-test (that is related to the brochure).
Study: NCT04410211

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Incidence of side effects such as excitation, headache, apnea, airway obstructions are recorded. Patients who experiences severe excitation disinhibition as defined in the investigator's opinion as agitation. Uncontrollable patient movements that causes unsafe procedural conditions and conversion to general anaesthesia is needed~Post procedural recovery scoring are taken which includes:~1. Time taken from the point that the procedure ended to the first OAAS score of 5~2. Time taken from (a) to meeting discharge eligilibility~Pre and post procedure pyschometric test (delayed and immediate memory test, posting box test and Stroop test) will be done and compared by the blinded observer/investigator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam injection
Description: Incidence of side effects such as excitation, headache, apnea, airway obstructions are recorded. Patients who experiences severe excitation disinhibition as defined in the investigator's opinion as agitation. Uncontrollable patient movements that causes unsafe procedural conditions and conversion to general anaesthesia is needed~Post procedural recovery scoring are taken which includes:~1. Time taken from the point that the procedure ended to the first OAAS score of 5~2. Time taken from (a) to meeting discharge eligilibility~Pre and post procedure pyschometric test (delayed and immediate memory test, posting box test and Stroop test) will be done and compared by the blinded observer/investigator.
Study: NCT03619954

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells infusion
Description: Pretreatment：patients enrolled in this study will receive 20 mg/kg of cyclophosphamide for solid tumor or 20-60 mg/kg of cyclophosphamide for hematological tumor once daily for 3 times. NK cells infusion is allowed within 2-14 days after treatment.~NK cells infusion：30-60 minutes before infusion，ant-allergic agents are applied (promethazine 25mg,i.m. ; Cimetidine 0.4g i.v. ; diphenhydramine 50mg po.). NK cells are intravenously infused into patients with 15-30 minutes every other day for one to three times. The number of every infused NK cells is 1-3×10\^7/kg, counted as the number of CD56+ cells. Patients with severe pleural or ascites can also receive pleural or abdominal cavity perfusion simultaneously. The total number of infused NK cells is no more than 5×10\^9 cells. 4 hours after NK cells infusion，IL-2 is applied every other day for six times
Study: NCT02061501

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optometric therapy during 6 months
Description: Optometric therapy during 6 months, once a week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optometric therapy during 12 months
Description: Optometric therapy once a week, during 12 months
Study: NCT03217240

Intervention type: PROCEDURE
Intervention: Cardiac Magnetic Resonance - MRI
Description: All participants will have to undergo CMR which uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images. Participants will be asked to lie on a narrow bed placed inside of a large magnet for about 1 hour. Several sets of images are needed. Participants are required to stay very still and follow the instruction of the MRI technologist who operates the machine from a room next door.

Intervention type: PROCEDURE
Intervention: Cardiac Magnetic Resonance - MRI
Description: All participants will have to undergo CMR which uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images. Participants will be asked to lie on a narrow bed placed inside of a large magnet for about 1 hour. Several sets of images are needed. Participants are required to stay very still and follow the instruction of the MRI technologist who operates the machine from a room next door.
Study: NCT02845999

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogenic immunotherapy based on Natural Killer cells adoptive transfer
Description: day -1 : donor NK cell purification ; day 0 : adoptive transfer (according to a dose escalation) ; Dose escalation protocol : 3.10\^6 ; 8.10\^6 and 12.10\^6 cells/kg of recipient body weight
Study: NCT01458873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium bicarbonate 4.2%
Description: diluted sodium bicarbonate 50 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diluted sodium bicarbonate 2.1%
Description: 50ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 50ml
Study: NCT02174380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Household Contact Evaluation
Description: Active evaluation of TB household contacts will be introducted as a new intervention in the district. The intervention will be undertaken by routine public health staff under routine conditions, however the assignment, training, monitoring and supervision of this intervention will occur in a stepped wedge roll out.
Study: NCT03578575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danggui Buxue Tang
Description: Danggui Buxue Tang is an extracted powder of traditional Chinese medicine formula.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a very low dose Danggui Buxue Tang powder.
Study: NCT02845999

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: day -8 : cetuximab 400 mg/m2 ; day -1 and every week (for 7 weeks) : cetuximab 250 mg/m2
Study: NCT03749486

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Cataract surgery will be done following ArcScan measurement
Study: NCT01310270

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pro-Omega
Description: Pro-Omega, 4.4gm/day x 1 month
Study: NCT03217240

Intervention type: OTHER
Intervention: Cardiopulmonary Exercise Test
Description: Participants will be asked to undergo a cardiopulmonary exercise test (CPET). Participants will need to wear a mask. Several electrodes will be placed on the chest to record heart activity during exercise. Participants will need to pedal for at least 8-12 minutes. Pedalling will be instructed to report any symptoms such as chest discomfort, shortness of breath, leg fatigue or dizziness. A small probe will be placed on participant's finger during the test to measure the oxygen content in the blood. Immediately after exercising, participants will rest for 5-10 minutes while the blood pressure and electrocardiogram are monitored. The results will be read by a cardiologist.
Study: NCT02845999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: day -6 : cyclophosphamide 60 mg/Kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: day -6 to day -2 : fludarabine 25 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interleukin-2
Description: day -1 : addition of 1000 UI/ml of interleukin 2 to NK cells and overnight culture at 37°C, 5%CO2 ; day 0, hour +12 : 10 MUI of interleukin 2 injection, 2 times a week during 3 weeks.
Study: NCT02382289

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency ablation for sacroiliac joint arthropathy
Description: comparing bipolar RF at 6 points with monopolar RF at 3 and 6 points for the treatment of SI arthropathy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency ablation for sacroiliac joint arthropathy
Description: comparing bipolar RF at 6 points with monopolar RF at 3 and 6 points for the treatment of SI arthropathy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency ablation for sacroiliac joint arthropathy
Description: comparing bipolar RF at 6 points with monopolar RF at 3 and 6 points for the treatment of SI arthropathy
Study: NCT03684525

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraction of primary canines
Description: At Baseline (T0): Clinical examinatiion + CBCT scan and then both primary canines will be extracted At 6 month follow-up (T1): Clinical examination only At 12 month follow-up: Clinical examination +/- CBCT scan~Treatment Plan :~* If displaced canine is not erupted and no improvement in position radiographically is noticed, patient will be referred to orthodontic/oral surgery department~* If Canine is emerged to oral cavity: No further CBCT scan will be taken~* If Position of canine is improved radiographically: Follow up untill canine emerges, total observation time is 18 months
Study: NCT01436357

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh3NSmut1
Description: Stages I and II: Receive AdCh3NSmut1 at 2.5 x 10\^10 total virus particles (vp)/dose, intramuscularly on day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-NSmut
Description: Stages I and II: 1 dose of MVA-NSmut at the dosage 1.8 x10\^8 plaque forming units (pfu) intramuscularly on day 56.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Stages I and II: Two doses of placebo intramuscularly, 1 at day 0 and 1 at day 56.
Study: NCT03217318

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ureteral stenting with standard or modified ureteral stent
Description: Ureteral stenting because of kidney and or ureteral stones at the iliacal vessel crossing of the ureter or proximally

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ureteral stenting with standard or modified ureteral stent
Description: Ureteral stenting because of kidney and or ureteral stones at the iliacal vessel crossing of the ureter or proximally
Study: NCT04459923

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided erector spinae plane block catheter
Description: for postoperative pain management ultrasound-guided erector spine plane block catheter placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural catheter
Description: for postoperative pain management thoracic epidural catheter placement
Study: NCT04520867

Intervention type: OTHER
Intervention: STRENGTH
Description: Patients with esophageal (EC) and gastroesophageal junction (GEJC) cancers who are seen in the Esophageal and Gastric Multidisciplinary Clinic (EGMDC) for treatment planning and are recommended to receive neoadjuvant therapy and plan to receive treatment at UCCC Metro will be offered enrollment into the study. Patients will complete the patient reported assessments focused on QOL and physical activity on provided tablet computers during UCCC visits at specified time points. If unable to complete assessments in person they will be e-mailed to the patient via REDCap to complete. Additional data regarding dosing of chemotherapy, radiation, nutrition and surgical outcomes will be collected.